| scholarly article | Q13442814 |
| P50 | author | David A Harris | Q39486896 |
| P2093 | author name string | Luana Fioriti | |
| Roberto Chiesa | |||
| Emiliano Biasini | |||
| Bettina Drisaldi | |||
| Elena Quaglio | |||
| Richard S Stewart | |||
| Cheryl Adles | |||
| Leanne R Stewart | |||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endoplasmic reticulum | Q79927 |
| P304 | page(s) | 21732-21743 | |
| P577 | publication date | 2003-03-26 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation | |
| P478 | volume | 278 |
| Q46933074 | 6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation |
| Q57372328 | A Transmembrane Form of the Prion Protein Is Localized in the Golgi Apparatus of Neurons |
| Q33436060 | Activation of p53-regulated pro-apoptotic signaling pathways in PrP-mediated myopathy |
| Q37377977 | Activation of the unfolded protein response and granulovacuolar degeneration are not common features of human prion pathology |
| Q33447171 | Alternative translation initiation generates cytoplasmic sheep prion protein |
| Q34800606 | An N-terminal polybasic domain and cell surface localization are required for mutant prion protein toxicity |
| Q36177322 | An overview of transmissible spongiform encephalopathies |
| Q30498795 | Beta-subunits promote the expression of Ca(V)2.2 channels by reducing their proteasomal degradation |
| Q46211967 | Biosynthesis of prion protein nucleocytoplasmic isoforms by alternative initiation of translation |
| Q28585293 | Both raft- and non-raft proteins associate with CHAPS-insoluble complexes: some APP in large complexes |
| Q40496138 | Calpain and other cytosolic proteases can contribute to the degradation of retro-translocated prion protein in the cytosol |
| Q42801235 | Can intrabodies targeted to the secretory compartment interact with a cytosolic protein? A comment on the article by Sawahata et al. "Cytoplasmic expression and specific binding of the VH/VL single domain intrabodies in transfected NIH3T3 cells", |
| Q36863767 | Canadian Association of Neurosciences Review: prion protein and prion diseases: the good and the bad. |
| Q57083664 | Cannibals and garbage piles |
| Q40348579 | Catabolism of endogenous and overexpressed APH1a and PEN2: evidence for artifactual involvement of the proteasome in the degradation of overexpressed proteins |
| Q44386982 | Cell surface expression of the prion protein in yeast does not alter copper utilization phenotypes |
| Q33742065 | Cell type-specific neuroprotective activity of untranslocated prion protein |
| Q46383132 | Cell type-specific transgene expression of the prion protein in Xenopus intermediate pituitary cells |
| Q36006619 | Cellular prion protein neuroprotective function: implications in prion diseases |
| Q39722913 | Changing the solvent accessibility of the prion protein disulfide bond markedly influences its trafficking and effect on cell function |
| Q57083642 | Chapter 10 Prions |
| Q57372680 | Characterization of the Properties and Trafficking of an Anchorless Form of the Prion Protein |
| Q38864129 | Comparative Haploid Genetic Screens Reveal Divergent Pathways in the Biogenesis and Trafficking of Glycophosphatidylinositol-Anchored Proteins. |
| Q34408461 | Compartment-restricted biotinylation reveals novel features of prion protein metabolism in vivo |
| Q52927715 | Copper is required for prion protein-associated superoxide dismutase-I activity in Pichia pastoris. |
| Q34977281 | Cytosolic aggregates perturb the degradation of nontranslocated secretory and membrane proteins |
| Q37142665 | Cytosolic prion protein is the predominant anti-Bax prion protein form: exclusion of transmembrane and secreted prion protein forms in the anti-Bax function |
| Q24300029 | Cytosolic quality control of mislocalized proteins requires RNF126 recruitment to Bag6 |
| Q42947659 | Dangerous liaisons between a microbe and the prion protein |
| Q34812498 | Development of kinomic analyses to identify dysregulated signaling pathways in cells expressing cytoplasmic PrP. |
| Q28477995 | Expression of mutant or cytosolic PrP in transgenic mice and cells is not associated with endoplasmic reticulum stress or proteasome dysfunction |
| Q39284075 | Failure of prion protein oxidative folding guides the formation of toxic transmembrane forms. |
| Q35938198 | Folding and misfolding of the prion protein in the secretory pathway |
| Q33501189 | Functionally relevant domains of the prion protein identified in vivo |
| Q36876512 | GFP-tagged mutant prion protein forms intra-axonal aggregates in transgenic mice |
| Q38621484 | Genetic human prion disease modelled in PrP transgenic Drosophila. |
| Q40508891 | Genetic mapping of activity determinants within cellular prion proteins: N-terminal modules in PrPC offset pro-apoptotic activity of the Doppel helix B/B' region |
| Q35794935 | Glycosylation of prion strains in transmissible spongiform encephalopathies |
| Q36083479 | Human and animal spongiform encephalopathies are autoimmune diseases: a novel theory and its supporting evidence |
| Q49501643 | Impaired transport of intrinsically disordered proteins through the Sec61 and SecY translocon; implications for prion diseases |
| Q38544726 | Increased expression of p62/SQSTM1 in prion diseases and its association with pathogenic prion protein |
| Q36716367 | Inhibition of the FKBP family of peptidyl prolyl isomerases induces abortive translocation and degradation of the cellular prion protein |
| Q36856446 | Insights into prion strains and neurotoxicity |
| Q48417052 | Insoluble aggregates and protease-resistant conformers of prion protein in uninfected human brains. |
| Q27937610 | Limited ER quality control for GPI-anchored proteins. |
| Q33493430 | Loss of anti-Bax function in Gerstmann-Sträussler-Scheinker syndrome-associated prion protein mutants |
| Q39250023 | Lysosomal Quality Control in Prion Diseases |
| Q35597106 | Making sense of mass destruction: quantitating MHC class I antigen presentation |
| Q35639302 | Mammalian prion biology: one century of evolving concepts |
| Q38800950 | Mechanisms of prion-induced neurodegeneration. |
| Q39015438 | Misfolding leads the way to unraveling signaling pathways in the pathophysiology of prion diseases. |
| Q33338476 | Molecular distinction between pathogenic and infectious properties of the prion protein |
| Q40280647 | Molecular morphology and toxicity of cytoplasmic prion protein aggregates in neuronal and non-neuronal cells |
| Q28508384 | Mutant PrP suppresses glutamatergic neurotransmission in cerebellar granule neurons by impairing membrane delivery of VGCC α(2)δ-1 Subunit |
| Q33812876 | Mutant prion protein expression is associated with an alteration of the Rab GDP dissociation inhibitor alpha (GDI)/Rab11 pathway |
| Q48219838 | Mutational analysis of topological determinants in prion protein (PrP) and measurement of transmembrane and cytosolic PrP during prion infection |
| Q46412720 | Neurodegenerative illness in transgenic mice expressing a transmembrane form of the prion protein. |
| Q37135556 | Neuroprotective properties of the PrP-like Shadoo glycoprotein assessed in the middle cerebral artery occlusion model of ischemia |
| Q46734839 | Non-infectious aggregates of the prion protein react with several PrPSc-directed antibodies. |
| Q37066530 | Opposing roles of prion protein in oxidative stress- and ER stress-induced apoptotic signaling |
| Q33581647 | Perturbation of endoplasmic reticulum homeostasis facilitates prion replication. |
| Q48237260 | Post-translational import of the prion protein into the endoplasmic reticulum interferes with cell viability: a critical role for the putative transmembrane domain |
| Q46498597 | PrP-containing aggresomes are cytosolic components of an ER quality control mechanism. |
| Q50908801 | Prion Diseases. |
| Q46801132 | Prion clearance in bigenic mice |
| Q36521947 | Prion diseases of humans and farm animals: epidemiology, genetics, and pathogenesis |
| Q35602374 | Prion diseases: from molecular biology to intervention strategies |
| Q36767231 | Prion neurotoxicity: insights from prion protein mutants |
| Q42068269 | Prion pathogenesis is independent of caspase-12. |
| Q35094535 | Prion protein biosynthesis and its emerging role in neurodegeneration |
| Q33786940 | Prion protein misfolding affects calcium homeostasis and sensitizes cells to endoplasmic reticulum stress |
| Q35172963 | Prion protein trafficking and the development of neurodegeneration |
| Q37316540 | Prion protein with an insertional mutation accumulates on axonal and dendritic plasmalemma and is associated with distinctive ultrastructural changes. |
| Q35167510 | Prion proteins meet protein quality control |
| Q36628157 | Prions and their partners in crime |
| Q54224345 | Prions, prionoids and protein misfolding disorders. |
| Q41062579 | Progress and problems in the biology, diagnostics, and therapeutics of prion diseases |
| Q92299716 | Proteasomal Inhibition Redirects the PrP-Like Shadoo Protein to the Nucleus |
| Q37671821 | Protection from cytosolic prion protein toxicity by modulation of protein translocation |
| Q38793449 | Protein Quality Control in Health and Disease |
| Q35147351 | Protein targeting and degradation are coupled for elimination of mislocalized proteins |
| Q90740558 | Quality Control of Orphaned Proteins |
| Q57794693 | Rapid degradation of progressive ankylosis protein (ANKH) in craniometaphyseal dysplasia |
| Q35990277 | Rational targeting for prion therapeutics. |
| Q47926972 | Recognition of lumenal prion protein aggregates by post-ER quality control mechanisms is mediated by the preoctarepeat region of PrP. |
| Q30483989 | Reduced translocation of nascent prion protein during ER stress contributes to neurodegeneration |
| Q42198482 | Regulation of sub-compartmental targeting and folding properties of the Prion-like protein Shadoo |
| Q36796856 | Retrotranslocation of prion proteins from the endoplasmic reticulum by preventing GPI signal transamidation |
| Q28507433 | SUMOylation Is an Inhibitory Constraint that Regulates the Prion-like Aggregation and Activity of CPEB3 |
| Q33471412 | Selective processing and metabolism of disease-causing mutant prion proteins |
| Q34633462 | Selective re-routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrP(Sc) formation |
| Q33689595 | Signal sequence insufficiency contributes to neurodegeneration caused by transmembrane prion protein |
| Q43158356 | Strain-associated variations in abnormal PrP trafficking of sheep scrapie |
| Q36393488 | Stressing out the ER: a role of the unfolded protein response in prion-related disorders |
| Q38356292 | Subcellular distribution of the prion protein in sickness and in health |
| Q33264756 | Substrate-specific translocational attenuation during ER stress defines a pre-emptive quality control pathway |
| Q37393121 | Synaptic dysfunction in prion diseases: a trafficking problem? |
| Q40441816 | Tau is not normally degraded by the proteasome |
| Q60290979 | The C-terminal Globular Domain of the Prion Protein Is Necessary and Sufficient for Import into the Endoplasmic Reticulum |
| Q38853404 | The Protein-disulfide Isomerase ERp57 Regulates the Steady-state Levels of the Prion Protein. |
| Q47586836 | The Sec61/SecY complex is inherently deficient in translocating intrinsically disordered proteins |
| Q36003019 | The cellular prion protein (PrP(C)): its physiological function and role in disease |
| Q37285520 | The consequences of pathogenic mutations to the human prion protein |
| Q27015793 | The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology |
| Q33564834 | The efficiency of protein compartmentalization into the secretory pathway |
| Q39680946 | The hydrophobic core region governs mutant prion protein aggregation and intracellular retention |
| Q40305093 | The interaction between cytoplasmic prion protein and the hydrophobic lipid core of membrane correlates with neurotoxicity |
| Q28288758 | The state of the prion |
| Q35558459 | The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. |
| Q36555039 | Traffic of prion protein between different compartments on the neuronal surface, and the propagation of prion disease |
| Q38341877 | Trafficking and degradation pathways in pathogenic conversion of prions and prion-like proteins in neurodegenerative diseases |
| Q35448997 | Transgenic fatal familial insomnia mice indicate prion infectivity-independent mechanisms of pathogenesis and phenotypic expression of disease |
| Q40796560 | Transgenic mice recapitulate the phenotypic heterogeneity of genetic prion diseases without developing prion infectivity: Role of intracellular PrP retention in neurotoxicity |
| Q34289917 | Transmissible spongiform encephalopathies. |
| Q40498670 | Trapping prion protein in the endoplasmic reticulum impairs PrPC maturation and prevents PrPSc accumulation |
| Q35710420 | Ubiquitin-specific protease 14 modulates degradation of cellular prion protein |
| Q26773443 | Unfolded Protein Response and Macroautophagy in Alzheimer's, Parkinson's and Prion Diseases |
Search more.